Total number of projects: 6
As coordinator: 0
As participant: 6
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2014 | 0 | 5.993.000 | 650.444 | 1 | ||
2012 | 0 | 4.976.953 | 442.502 | 2 | ||
2011 | 0 | 15.478.025 | 3.620.463 | 2 | ||
2010 | 0 | 1.471.272 | 153.912 | 1 |
Total number of partners: 487
Partner loyalty:
Frequent Partner: (> 2 projects): 100
Rare Partner: 387
Frequent / Rare Partner Ratio: 0.26
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2014-02-01 | Treatment of late onset bacterial sepsis caused by vancomycin susceptible bacteria in neonates and infants aged under three months | NEOVANC | participant | 5.993.000 | 12 |
2012-01-01 | NCDs and their social determinants in Mediterranean partner countries: building sustainable research capacity for effective policy intervention | RESCAP-MED | participant | 1.986.255 | 12 |
2012-01-01 | A stealth attack tool for preventing clinical drug resistance through a unique self-regenerating surface | BacAttack | participant | 2.990.698 | 7 |
2011-12-01 | Targeting Brain Inflammation For Improved Functional Recovery in Acute Neurodegenerative Disorders | TargetBraIn | participant | 11.989.162 | 10 |
2011-08-01 | Exploiting plants for the production of future generation recombinant pharmaceuticals | Future-Pharma | participant | 3.488.863 | 2 |
2010-12-01 | Easy and rapid generation of light-emitting somatic-transgenic mice to monitor specific disease states and to screen effective drugs | SomaBio | participant | 1.471.272 | 3 |